Sustainable growth
Alcon has completed its separation from Novartis


Colin Kerr
Published: Saturday, June 1, 2019
Alcon has completed its separation from Novartis and the company’s shares are now trading on the SIX Swiss Exchange and New York Stock Exchange (NYSE) under the symbol “ALC.”
“For more than 70 years, Alcon has been dedicated to helping people see brilliantly and now, as an independent company, we are pursuing even more opportunities to further that mission,” said David Endicott, Chief Executive Officer of Alcon. “We are poised to achieve sustainable growth and create long-term shareholder value as a standalone company. As a nimble medical device company, we are sharply focused on providing innovative products that meet the needs of our customers, patients and consumers.”
https://www.alcon.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.